Skip to main content
. Author manuscript; available in PMC: 2014 May 22.
Published in final edited form as: Immunobiology. 2011 Jan 12;216(8):918–924. doi: 10.1016/j.imbio.2011.01.007

Table 1.

PD-1 is required to prevent rejection of male islet grafts in sensitized recipients.

Group Islet Donor Recipients Anti-PD-1 treatment Graft Survival (d) % Graft survival
1 Male PD-1−/− N/Aa 10 × 2, 14, 18, 20 × 2, 28, 76b 0
2 Female PD-1−/− N/A > 100 × 5 100
3 Male BTLA−/− None 44, > 100 × 3 75
4 Male WT None > 100 × 7 100
5 Male WT At Immunization 15, 16, > 100 × 3 60
6 Male WT At Transplantation 20, > 100 × 4 80
7 Male WT At Immunization & Transplantation 17, 19, 28, > 100 25

Female WT or PD-1−/− or BTLA−/− mice were immunized with male splenocytes two weeks before transplantation of islet grafts. The sensitized PD-1−/− mice given male islets (group 1) were significantly different (P< 0.01) from groups 2, 3, and 4. For groups 5–7, female WT mice were treated with anti-PD-1 at the time of immunization with male splenocytes or at the time of transplantation of male islets, 2 weeks after immunization or at both stages. Group 7 vs. 4 (P> 0.05).

a

N/A, not applicable

b

Group 1 recipients (n=8) of male islets received islets from WT B6 (n=4) or PD-1−/− B6 (n=4) donors.